Annotation

British Journal of Haematology

Volumn 89, Issue 3, 1995, Pages 431-439

  Chong, Benc H ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

heparin; thrombocytopenia

Indexed keywords

ANCROD; DANAPAROID; FIBRINOLYTIC AGENT; HEPARIN; HEPARINOID; HIRUDIN; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; WARFARIN;

HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; CARDIOVASCULAR SURGICAL PROCEDURES; HEPARIN; HUMAN; IMMUNOLOGIC DISEASES; PLATELET AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0028923741     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1995.tb08346.x     Document Type: Article

References (100)

1. Prevention of heparin‐induced thrombocytopenia during open heart surgery with iloprost
2. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin‐induced thrombocytopenia
3. Heparin‐induced thrombocytopenia and recurrent thromboembolism
4. Insights into heparin‐induced thrombocytopenia
5. Heparin‐associated acute adrenal insufficiency. (Letter)
6. Heparin‐induced immune thrombocytopenia
7. Heparin‐associated thrombocytopenia: a comparison of three heparin preparations
8. Thrombocytopenia occurring during the administration of heparin: a prospective study in 52 patients
9. The white clot syndrome or heparin‐associated thrombocytopenia and thrombosis (WCS or HATT): 26 cases
10. Substitution of antithrombin a III in shock and DIC: a randomized study
11. Heparin‐induced thrombopenia
12. Heparin‐induced thrombocytopenia and thrombosis: clinical and laboratory studies
13. Heparin‐induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions
14. Thrombopenia and disseminated intravascular coagulation during treatment with heparin: two cases with neurological complications. (Review)
15. Heparin‐induced thrombocytopenia
16. Heparin‐induced thrombocytopenia
17. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin‐induced thrombocytopenia
18. Platelet proaggregating effect of heparin: possible mechanism for non‐immune heparin‐associated thrombocytopenia
19. Heparin‐induced thrombocytopenia: further studies of the effects of heparin‐dependent antibodies on platelets
20. Heparin‐induced thrombocytopenia: effects of rabbit IgG, and its Fab and Fc fragments on antibody‐heparin platelet interaction
21. Heparin‐induced thrombocytopenia: mechanism of Interaction of the heparin‐dependent antibody with platelets
22. Heparin‐induced thrombocytopenia: effect of heparin platelet antibody on platelets
23. The mechanism of heparin‐induced platelet aggregation
24. Heparin‐induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172
25. Plasma P‐selectin is increased in thrombotic consumptive platelet disorders
26. Increased expression of platelet IgG Fc receptors in immune heparin‐induced thrombocytopenia
27. Heparin‐induced thrombocytopenia: association of thrombotic complications with heparin‐dependent IgG antibody that induces thromboxane synthesis and platelet aggregation
28. Heparin‐associated thrombocytopenia
29. Immune endothellal cell injury in heparin‐associated thrombocytopenia
30. Thrombolytic therapy in heparin‐associated thrombocytopenia with thrombosis
31. Heparin‐associated thrombocytopenia and thrombosis: optimal therapy with ancrod. (Review)
32. Iloprost (Ilomedine) and extracorporeal circulation with conventional heparinization in a patient with heparin‐induced thrombocytopenia
33. Rapid anticoagulation using ancrod for heparin‐induced thrombocytopenia
34. Heparin‐associated thrombocytopenia in the neurosurgical patient
35. Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin
36. The heparin‐induced thrombosis‐thrombocytopenia syndrome
37. Severe thrombopenia from heparin: value of the use of low molecular weight heparin: apropos of six cases
38. Low molecular weight heparin‐induced thrombocytopenia complicated by massive pulmonary embolism and acute myocardial infarction: a case report. (Abstract)
39. Perioperative paraplegia and multiorgan failure from heparin‐induced thrombocytopenia
40. Correction of severe heparin‐associated thrombocytopenia with intravenous immunoglobulin
41. Safety and efficiency of warfarin started early after submissive venous thrombosis or pulmonary embolism
42. Cardiovascular surgery and heparin‐induced thrombocytopenia
43. Heparin‐induced thrombocytopenia. (Heparin supplement)
44. Low molecular weight heparin fractions as an alternative therapy in heparin‐induced thrombocytopenia
45. Heparin‐associated thrombocytopenia: successful therapy with the hepartnoid Org 10172 in a patient showing cross‐reaction to LMW heparins
46. Heparin‐associated thrombocytopenia: the antibody is not heparin specific
47. Further evidence that alpha‐granule components such as platelet factor 4 are involved in platelet‐IgG‐heparin interactions during heparin‐associated thrombocytopenia
48. Specific quantification of heparin‐dependent antibodies for the diagnosis of heparin‐associated thrombocytopenia using an enzyme‐linked immunosorbent assay
49. Treatment of heparin‐induced thrombocytopenia with thrombosis by new heparinoid
50. Phenomenon of heparin‐induced thrombocytopenia associated with skin necrosis. (Review)
51. An enzyme‐linked immunosorbent assay for the evaluation of thrombocytopenia induced by heparin
52. Platelet aggregation studies for the diagnosis of heparin‐induced thrombocytopenia
53. Heparin‐induced platelet activation in sixteen surgical patients: diagnosis and management
54. Intraoperative management of patients with heparin‐induced thrombocytopenia
55. Heparin‐induced thrombocytopenia, thrombosis and haemorrhage
56. Heparin‐induced thrombocytopenia: laboratory studies
57. Heparin‐associated thrombocytopenia
58. Thrombogenic thrombopenia related to heparin. Clinical biological and therapeutic results: apropos of 32 cases
59. Further evidence that heparin‐dependent thrombocytopenia may result from Fc receptor‐mediated interactions
60. The heparin‐induced thrombocytopenia syndrome: an update
61. Re‐exposure to heparin of patients with heparin‐associated antibodies
62. Heparin‐coated catheters and heparin‐induced thrombocytopenia
63. Myocardial infarction and massive biventricular thrombosis during thrombocytopenia induced by pentosan polysulfate and heparin
64. Spontaneous platelet aggregation in heparin‐treated patients
65. Treatment of heparin‐associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216)
66. Heparin‐associated thrombocytopenia antibody binding specificity to platelet antigens
67. Heparin‐induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172)
68. Management of patients with heparin‐associated thrombocytopenia and thrombosis requiring cardiac surgery
69. Treatment of K heparin‐induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor
70. Effect of aspirin on heparin‐induced thrombocytopenia (HIT) in a patient requiring hemodialysis
71. Heparin‐induced thrombocytopenia and thrombosis: reversal with streptokinase: a case report and review of literature. (Review)
72. Heparin‐induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease
73. Hirudin therapy for heparin‐associated thrombocytopenia and deep venous thrombosis
74. Plasmapheresis in the management of heparin‐associated thrombocytopenia with thrombosis
75. Heparin‐induced thrombocytopenia
76. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin‐induced thrombocytopenia and thrombosis
77. Different platelet specificities of heparin‐dependent platelet aggregation factors in heparin‐associated immune thrombocytopenia
78. Studies on the mechanism of the human platelet release reaction by immunologic stimuli. III. Relationship between the binding of soluble IgG aggregates to the Fc receptor and cell response in the presence and absence of plasma
79. Studies of the frequency of heparin‐associated thrombocytopenia
80. Heparin‐induced thrombocytopenia. Eight cases with thrombotic‐haemorrhagic complications
81. Effect of heparin and heparin fractions on platelet aggregation
82. Heparin‐associated thrombocytopenia: a critical review and a pooled analysis
83. A diagnostic test for heparin‐induced thrombocytopenia
84. Heparin‐induced thrombocytopenia: use of indirect immunofluorescence
85. Complications from heparin‐induced thrombocytopenia in patients undergoing cardiopulmonary bypass
86. Current controversies concerning the measurement of platelet‐associated IgG
87. Surgical management of heparin‐associated thrombocytopenia: strategies in the treatment of venous and arterial thromboembolism
88. Adrenal hemorrhagic necrosis related to heparin‐associated thrombocytopenia
89. Ancrod anticoagulation for cardiopulmonary bypass in heparin‐induced thrombocytopenia and thrombosis
90. Plasma exchange and heparin‐induced thrombocytopenia
91. White clot syndrome; peripheral vascular complications of heparin therapy
92. Heparin‐related immune thrombocytopenia: studies of antibody‐heparin specificity
93. Delayed‐onset heparin‐induced thrombocytopenia: a potentially malignant syndrome
94. Heparin‐associated thrombocytopenia: treatment of low molecular weight heparin
95. Thrombocytopenia associated with antiheparin antibody
96. Heparin‐induced thrombocytopenia in open heart surgical patients: sequelae of late recognition
97. Heparin‐induced thrombocytopenia
98. Heparin‐induced thrombocytopenia is more common with unfractionated heparin than with low molecular weight heparin. (Abstract)